MetaVia Doses First Patient in Higher-Dose Phase 1 Trial for Obesity Drug DA-1726

summarizeSummary

MetaVia Inc. announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a dual GLP-1 and glucagon agonist for obesity, focusing on higher doses to optimize tolerability and efficacy.

check_boxKey Events

• Clinical Trial Advancement

  MetaVia Inc. has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual GLP-1 and glucagon agonist for obesity.

• Higher Dose Evaluation

  Part 3 of the Phase 1 program consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies to safely achieve higher target doses (up to 64 mg) and further optimize tolerability.

• Promising Early Data

  Previous results from the trial showed approximately 9% weight loss at the 48 mg dose, along with meaningful reductions in waist circumference, improved glycemic control, and early signals of direct liver benefit.

• Strategic Importance

  This clinical progress is critical for MetaVia, a company with a going concern warning and recent dilutive capital raises, providing a positive catalyst amidst financial challenges.

auto_awesomeAnalysis

This 8-K reports a significant clinical milestone for MetaVia, a clinical-stage biotechnology company facing a going concern warning and recent dilution. Advancing its lead obesity drug, DA-1726, into higher-dose cohorts of its Phase 1 trial is crucial. The company aims to build on previous promising results, including 9% weight loss, by optimizing dosing for improved tolerability and differentiated efficacy in the competitive obesity market. This positive development provides a much-needed boost to investor confidence and extends the company's clinical pipeline progress, which is vital for its long-term viability. Data from this part of the study is expected in Q4 2026.